Loading clinical trials...
Loading clinical trials...
A Phase Ib/II Trial to Evaluate Safety, Tolerability and Efficacy of Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for Patients With EGFR-Mutant Non-Small Cell Lung Cancer
Conditions
Interventions
Aurora A Kinase Inhibitor LY3295668
Osimertinib
Locations
1
United States
M D Anderson Cancer Center
Houston, Texas, United States
Start Date
February 17, 2022
Primary Completion Date
June 30, 2026
Completion Date
June 30, 2026
Last Updated
April 24, 2026
NCT05198830
NCT06122064
NCT04751747
NCT05502523
NCT05624996
NCT03948100
Lead Sponsor
M.D. Anderson Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions